Social Prescribing for Depression: Acceptance and Participation in Mental Health, Quality of Life, and Social Inclusion – A Feasibility Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00037857

Enrollment

Registered

2025-12-01

Start date

2025-12-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F32 F33

Interventions

Group 1: Semi-structured interviews in 20 Patients before and after the program, as well as in 50 Patients psychological testing at the same time were conducted. All 50 Patients: multiple Visits to ar

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Persons capable of consenting, Patients with depressive disorder (ICD 10 F32 and F33)

Exclusion criteria

Exclusion criteria: Patients unable to consent, patients with other psychiatric diagnoses (primary diagnosis not F32 or F33), patients with acute psychiatric emergencies (e.g., acute suicidality, severe psychotic episode)

Design outcomes

Primary

Measure	Time frame
Feasibility of implementing social prescribing for depressive patients in Kaiserslautern	—

Secondary

Measure	Time frame
Semi-structured Interviews before and after the Intervention: How is the service being used? Can patients be motivated to actively participate? What is the willingness to integrate the service into primary care and psychiatric care? How can this integration be achieved? Before the start of the intervention and after its completion, the following assessment instruments will be administered to the 50 study participants: To assess depressive symptoms, the Patient Health Questionnaire-9 (PHQ-9) will be used as a self-report scale. Resilience will be measured using the German version of the Brief Resilience Scale (BRS). Current quality of life will be assessed with the WHOQOL-BREF. To evaluate perceived loneliness, the German version of the De Jong Gierveld Loneliness Scale (DJGLS) will be used, and participation will be measured using the Index for the Measurement of Restrictions on Participation (IMET).	—

Measure

Time frame

Semi-structured Interviews before and after the Intervention: How is the service being used? Can patients be motivated to actively participate? What is the willingness to integrate the service into primary care and psychiatric care? How can this integration be achieved? Before the start of the intervention and after its completion, the following assessment instruments will be administered to the 50 study participants: To assess depressive symptoms, the Patient Health Questionnaire-9 (PHQ-9) will be used as a self-report scale. Resilience will be measured using the German version of the Brief Resilience Scale (BRS). Current quality of life will be assessed with the WHOQOL-BREF. To evaluate perceived loneliness, the German version of the De Jong Gierveld Loneliness Scale (DJGLS) will be used, and participation will be measured using the Index for the Measurement of Restrictions on Participation (IMET).

—

Countries

Germany

Contacts

Public ContactJanina Geib

Klinik für Psychosomatik, Westpfalz-Klinikum Kaiserslautern

jgeib@westpfalz-klinikum.de+496312032734

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026